Eravacycline 2mg/kg + Eravacycline 1.5mg/kg
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infections (cIAI)
Conditions
Complicated Intra-abdominal Infections (cIAI)
Trial Timeline
May 22, 2025 → Mar 19, 2029
NCT ID
NCT06794541About Eravacycline 2mg/kg + Eravacycline 1.5mg/kg
Eravacycline 2mg/kg + Eravacycline 1.5mg/kg is a phase 2 stage product being developed by Innoviva for Complicated Intra-abdominal Infections (cIAI). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06794541. Target conditions include Complicated Intra-abdominal Infections (cIAI).
What happened to similar drugs?
4 of 20 similar drugs in Complicated Intra-abdominal Infections (cIAI) were approved
Approved (4) Terminated (3) Active (15)
🔄HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06794541 | Phase 2 | Recruiting |
Competing Products
20 competing products in Complicated Intra-abdominal Infections (cIAI)